FDG PET/CT in Monitoring Very Early Therapy Response in Patients With Glioblastoma

Sex: All

Ages: 18 Years – 99 Years

Healthy volunteers: No

Phase: NA

Enrollment: 7

Sponsor: Jonsson Comprehensive Cancer Center

Summary

This pilot clinical trial studies fluordeoxyglucose (fludeoxyglucose) F-18 (FDG) positron emission tomography (PET)/computed tomography (CT) in monitoring very early therapy response in patients with glioblastoma. Diagnostic procedures, such as FDG PET/CT, may help measure a patient's response to earlier treatment. Chemotherapy can induce very rapid changes to the tumor's glucose consumption which can be measured with imaging. FDG PET/CT shortly after the start of therapy may help identify very early therapy response in patients with glioblastoma.

Eligibility Criteria

Inclusion Criteria: * Patients with histologically proven high grade glioma * Intention to start therapy Exclusion Criteria: * Severe psychiatric illness * Inability to give written consent * Breast feeding / pregnancy

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT02902757). StuddyBuddy aggregates publicly available trial information.